A share price of Kymera Therapeutics Inc [KYMR] is currently trading at $63.37, up 3.44%. An important factor to consider is whether the stock is rising or falling in short-term value. The KYMR shares have gain 5.78% over the last week, with a monthly amount glided 5.81%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, B. Riley Securities reaffirmed its Buy rating on October 24, 2025, and elevated its price target to $80. On October 21, 2025, Mizuho initiated with a Outperform rating and assigned a price target of $81 on the stock. H.C. Wainwright reiterated its Buy rating and increased its price target to $70 on September 18, 2025. Barclays initiated its recommendation with a Overweight and recommended $60 as its price target on September 17, 2025. RBC Capital Mkts started tracking with a Outperform rating for this stock on September 16, 2025, and assigned it a price target of $70.
Kymera Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $19.44 and $63.96. Currently, Wall Street analysts expect the stock to reach $74.44 within the next 12 months. Kymera Therapeutics Inc [NASDAQ: KYMR] shares were valued at $63.37 at the most recent close of the market. An investor can expect a potential return of 17.47% based on the average KYMR price forecast.
Analyzing the KYMR fundamentals
Trailing Twelve Months sales for Kymera Therapeutics Inc [NASDAQ:KYMR] were 43.73M which represents -26.12% decline. Gross Profit Margin for this corporation currently stands at 0.89% with Operating Profit Margin at -7.6%, Pretax Profit Margin comes in at -6.75%, and Net Profit Margin reading is -6.75%. To continue investigating profitability, this company’s Return on Assets is posted at -0.27, Equity is -0.33 and Total Capital is -0.32. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 60.90 points at the first support level, and at 58.42 for the second support level. However, for the 1st resistance point, the stock is sitting at 65.20, and for the 2nd resistance point, it is at 67.02.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Kymera Therapeutics Inc [NASDAQ:KYMR] is 7.38. On the other hand, the Quick Ratio is 7.38, and the Cash Ratio is 1.58. Considering the valuation of this stock, the price to sales ratio is 104.26, the price to book ratio is 4.80.
Transactions by insiders
Recent insider trading involved Mainolfi Nello, Chief Executive Officer, that happened on Oct 29 ’25 when 30000.0 shares were sold. Officer, Mainolfi Nello completed a deal on Oct 29 ’25 to buy 30000.0 shares. Meanwhile, Chief Medical Officer Gollob Jared sold 59576.0 shares on Oct 15 ’25.
